RCE recce pharmaceuticals ltd

3.33%

31.0¢

Great post.This is has been a more testing time for me than the...

First 22 Last

Share
Profile

Follow
Gitmo

2,031 Posts.

312

28/10/20

11:56

Post #: 48450266
Share

Originally posted by elbarto: ↑

Morning gentlemen,
I also have wondered weather the algorithm was potentially someone who was involved with the CR, seeing that this all started soon after we had it. I wonder if the CR was offered to the market if we would be in this same space at the moment.
I’m currently sitting in the red with this share (averaged up substantially) however the trading parcel and volumes still lead me to believe that we are getting played by a larger stake holder.
Technically and fundamentally I believe we will be back to >1.30 before the year is out. all I can say is that if I had more money spare, I would be sinking it into RCE.
·HRECApproval to Start Phase I/II Burns Wound Study. Our toxicology profile to date on 327 are better than some commercial market drugs. We know that that this stuff works on rats, mice and dogs. Once we get a human result with an announcement saying “positive data from 327…” you can name your price on the value of RECCE. This clinical testing on tropical application of R327 is by itself a company maker and perhaps the testing I am most confident about success. We also only really require 2 weeks of testing and perhaps 2 weeks of data finalisation to see if it will be a deal maker. I feel like the FIDELITY have seen this and jumped on the chance to be involved with RECCE.
·RECCE® Compounds Selected by CSIRO/DohertyInstitute in Priority 1 Candidate Group for SARS-CoV-2 Antiviral ScreeningProgram (R327) According to the Program Selection Guidelines, Priority 1 status is defined as “highest or strong likelihood of antiviral or antiseptic efficacy – Compounds in this grouping will be eligible for stage 1 laboratory screening trials”. No set timeframe for result however November sometime.

·CMAX Clinical Trial Facility For Phase IStudy of Synthetic Antibiotic RECCE® 327. The Phase I clinical trial is a randomised, double blind, placebo-controlled single ascending dose study of 48 healthy adult subjects. The study seeks to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamic profile of RECCE® 327 following intravenous administration. Completion Q4 2020. THIS WILL BE HUGE. If we get the data back saying that R327 can be used on human trials for Phase II, you can kiss 1.50 goodbye.
Nervous times watching this share price fall, but the fall has come with no negative announcements and we have strong reason to believe that the algorithm has played a strong part in this. Buy when people are selling and sell when people are buying. Intuitive trading is something that goes against every neuron[B1] in the brain but one that more often than not pays off.
Good luck to all. I firmly believe in the science, data and fundamentals of RECCE. Its taken a long time to get to this point but from re reading old announcements this company could be valued in the billions in the coming years if all goes well.
[B1]

Expand

Great post.

This is has been a more testing time for me than the March lows to be honest. Im a pretty stubborn investor though. Unless there is a reason to sell based on fundamentals Im going to continue to hold. share price is just daily noise.

If something is released to market which changes my original investment thesis i will consider trimming my holding. Having entered at 24 cents a couple of years ago Im well and truly still ahead with this stock so granted makes it much easier to hold...

RCE Price at posting: 93.5¢ Sentiment: Buy Disclosure: Held
10 Upvote

0 Great analysis

Reply

Top Stories

HotCopper Highlights Week 26: Droneshield 2.0; Trigg re-jig & Virgin

RMX

Red Mountain: Chip samples point to 'large orogenic antimony mineral system' at Oaky Creek

SRL

Sunrise pops on top scandium hits NSW explorer will now use for 'multi-decade' plan

PAR

Paradigm Biopharmaceuticals makes key acquisition moving into FY26

Listen: HotCopper Wire Podcast 015 – Yeah, we're thinking the IPO market is back

NATO’s 5% target: Why Almonty Industries’ mega mine and NASDAQ listing are a perfect fit for investors

MVF

Monash IVF shares cater 25% – Disaster or deep-value play?

OCC

Orthocell sees 4% jump as Remplir used in first US surgery. But is that low?

Week 26 Wrap: Renewable gas fantasies; RBA July cut hope builds; copper's August peak?

BPH

Australia’s gas crisis is here – and dying coal plants aren’t helping

There are more pages in this discussion • 853 more messages in this thread...

First 22 Last

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last 31.0¢		Change 0.010(3.33%)		Mkt cap ! $89.39M

Open	High	Low	Value	Volume
31.0¢	32.0¢	30.0¢	$25.76K	82.29K

Buyers (Bids)

No.	Vol.	Price($)
2	13550	30.0¢

Sellers (Offers)

Price($)	Vol.	No.
31.0¢	18938	1

View Market Depth

No.	Vol.	Price($)
2	13550	0.300
2	34803	0.295
2	50000	0.290
4	131061	0.285
10	251389	0.280

Price($)	Vol.	No.
0.310	18938	1
0.320	5000	1
0.325	12600	1
0.330	114230	1
0.350	51319	4

Last trade - 16.10pm 27/06/2025 (20 minute delay)

RCE (ASX) Chart

Great post.This is has been a more testing time for me than the...

HotCopper Highlights Week 26: Droneshield 2.0; Trigg re-jig & Virgin

Red Mountain: Chip samples point to 'large orogenic antimony mineral system' at Oaky Creek

Sunrise pops on top scandium hits NSW explorer will now use for 'multi-decade' plan

Paradigm Biopharmaceuticals makes key acquisition moving into FY26

Listen: HotCopper Wire Podcast 015 – Yeah, we're thinking the IPO market is back

NATO’s 5% target: Why Almonty Industries’ mega mine and NASDAQ listing are a perfect fit for investors

Monash IVF shares cater 25% – Disaster or deep-value play?

Orthocell sees 4% jump as Remplir used in first US surgery. But is that low?

Week 26 Wrap: Renewable gas fantasies; RBA July cut hope builds; copper's August peak?

Australia’s gas crisis is here – and dying coal plants aren’t helping

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Great post.This is has been a more testing time for me than the...

Top Stories

HotCopper Highlights Week 26: Droneshield 2.0; Trigg re-jig & Virgin

Red Mountain: Chip samples point to 'large orogenic antimony mineral system' at Oaky Creek

Sunrise pops on top scandium hits NSW explorer will now use for 'multi-decade' plan

Paradigm Biopharmaceuticals makes key acquisition moving into FY26

Listen: HotCopper Wire Podcast 015 – Yeah, we're thinking the IPO market is back

NATO’s 5% target: Why Almonty Industries’ mega mine and NASDAQ listing are a perfect fit for investors

Monash IVF shares cater 25% – Disaster or deep-value play?

Orthocell sees 4% jump as Remplir used in first US surgery. But is that low?

Week 26 Wrap: Renewable gas fantasies; RBA July cut hope builds; copper's August peak?

Australia’s gas crisis is here – and dying coal plants aren’t helping

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News